Perspective Insights to Bio-Nanomaterials for the Treatment of Neurological Disorders.
biomaterials
central nervous system
drug delivery
neural-tissue engineering
neuro-imaging
neuro-sensing
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
06
2021
accepted:
20
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
The significance of biomaterials is well appreciated in nanotechnology, and its use has resulted in major advances in biomedical sciences. Although, currently, very little data is available on the clinical trial studies for treatment of neurological conditions, numerous promising advancements have been reported in drug delivery and regenerative therapies which can be applied in clinical practice. Among the commonly reported biomaterials in literature, the self-assembling peptides and hydrogels have been recognized as the most potential candidate for treatment of common neurological conditions such as Alzheimer's, Parkinson's, spinal cord injury, stroke and tumors. The hydrogels, specifically, offer advantages like flexibility and porosity, and mimics the properties of the extracellular matrix of the central nervous system. These factors make them an ideal scaffold for drug delivery through the blood-brain barrier and tissue regeneration (using stem cells). Thus, the use of biomaterials as suitable matrix for therapeutic purposes has emerged as a promising area of neurosciences. In this review, we describe the application of biomaterials, and the current advances, in treatment of statistically common neurological disorders.
Identifiants
pubmed: 34712651
doi: 10.3389/fbioe.2021.724158
pii: 724158
pmc: PMC8546296
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
724158Informations de copyright
Copyright © 2021 Khan, Rudrapal, Bhat, Ali, Alaidarous, Alshehri, Banwas, Ismail and Egbuna.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2017 Sep 14;8(1):533
pubmed: 28912446
J Pharmacol Exp Ther. 2010 Feb;332(2):429-36
pubmed: 19910538
J Cereb Blood Flow Metab. 2017 Mar;37(3):1030-1045
pubmed: 27174996
Mol Neurobiol. 2016 Mar;53(2):1108-1123
pubmed: 25586060
Adv Drug Deliv Rev. 2012 May 15;64(7):686-700
pubmed: 22100125
Future Sci OA. 2015 Sep 10;1(4):FSO71
pubmed: 28031922
Int J Mol Sci. 2020 May 04;21(9):
pubmed: 32375302
Int J Biol Macromol. 2016 Apr;85:141-9
pubmed: 26691383
Emergent Mater. 2021;4(1):293-312
pubmed: 33718777
Biomaterials. 2016 Oct;105:145-155
pubmed: 27521617
Ther Innov Regul Sci. 2019 Jan;53(1):120-127
pubmed: 29756484
Acta Biomater. 2016 Dec;46:177-190
pubmed: 27619837
J Biomater Appl. 2017 Feb;31(7):953-984
pubmed: 28178902
Biomed Mater. 2007 Dec;2(4):233-40
pubmed: 18458480
Mater Sci Eng C Mater Biol Appl. 2018 Sep 1;90:227-235
pubmed: 29853086
Biomaterials. 2010 Oct;31(30):7631-9
pubmed: 20656347
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Mol Pharm. 2020 Jan 6;17(1):338-348
pubmed: 31793786
J Am Chem Soc. 2015 Feb 18;137(6):2140-54
pubmed: 25474531
Int J Nanomedicine. 2012;7:3259-78
pubmed: 22848160
Drug Discov Today. 2018 May;23(5):1007-1015
pubmed: 29155026
ACS Nano. 2015 May 26;9(5):4850-71
pubmed: 25825926
Biomaterials. 2012 Oct;33(30):7435-46
pubmed: 22818980
Adv Drug Deliv Rev. 2019 Aug;148:219-238
pubmed: 31228483
Neuron. 2010 Jul 29;67(2):181-98
pubmed: 20670828
J R Soc Interface. 2008 Sep 6;5(26):957-75
pubmed: 18477539
Biomaterials. 2011 Sep;32(25):5906-14
pubmed: 21601921
Expert Opin Drug Deliv. 2019 Apr;16(4):453-466
pubmed: 30884987
Int J Pharm. 2020 Aug 30;586:119553
pubmed: 32561306
Cancer Gene Ther. 2021 Sep;28(9):911-923
pubmed: 33558704
Biomaterials. 2010 Sep;31(25):6519-29
pubmed: 20553982
Biomacromolecules. 2011 Jul 11;12(7):2735-45
pubmed: 21568346
Biomacromolecules. 2010 Oct 11;11(10):2724-30
pubmed: 20809645
Maturitas. 2013 Nov;76(3):272-8
pubmed: 23827471
Polymers (Basel). 2018 Feb 13;10(2):
pubmed: 30966220
Nanomedicine. 2011 Oct;7(5):560-71
pubmed: 21703989
Nanoscale. 2017 Nov 2;9(42):16281-16292
pubmed: 29046917
Anal Chim Acta. 2020 Apr 8;1105:147-154
pubmed: 32138913
Biochim Biophys Acta. 2009 Apr;1788(4):842-57
pubmed: 19061857
Free Radic Biol Med. 2013 Sep;62:132-144
pubmed: 23380027
Acta Biomater. 2020 Mar 1;104:76-84
pubmed: 31904559
Pharm Res. 2004 Aug;21(8):1362-73
pubmed: 15359570
Acta Biomater. 2015 Mar;15:77-88
pubmed: 25556361
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7483-7492
pubmed: 30923117
ACS Omega. 2019 Jul 29;4(7):12833-12840
pubmed: 31460408
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jan;13(1):e1664
pubmed: 32808486
Neuropsychopharmacology. 2014 Jan;39(1):169-88
pubmed: 24002187
Biochem Pharmacol. 2014 Apr 15;88(4):508-16
pubmed: 24462903
Eur J Neurosci. 2008 Sep;28(5):871-82
pubmed: 18717733
Front Cell Dev Biol. 2020 Aug 21;8:820
pubmed: 32974351
Expert Opin Drug Deliv. 2013 Mar;10(3):385-96
pubmed: 23289716
Adv Mater. 2017 Aug;29(32):
pubmed: 28650574
Biomed Mater. 2017 Mar 24;12(2):025014
pubmed: 28233757
Biophys Chem. 2010 Sep;151(1-2):1-9
pubmed: 20494507
Saudi J Biol Sci. 2020 Jul;27(7):1710-1716
pubmed: 32565686
Neurochem Int. 2021 Mar;144:104971
pubmed: 33515647
J Neurosci Res. 2012 Oct;90(10):1873-82
pubmed: 22714747
Stem Cells Dev. 2016 Feb 1;25(3):214-26
pubmed: 26577681
Biomaterials. 2017 Apr;123:77-91
pubmed: 28161683
Neural Regen Res. 2020 May;15(5):783-789
pubmed: 31719237
Biomaterials. 2014 Jan;35(2):664-74
pubmed: 24161168
Macromol Biosci. 2020 Sep;20(9):e2000149
pubmed: 32627956
Cerebrovasc Dis. 2009;27 Suppl 1:162-7
pubmed: 19342847
J Neural Eng. 2018 Oct;15(5):051002
pubmed: 29889043
Front Neurosci. 2020 Jun 09;14:494
pubmed: 32581676
Microsurgery. 2008;28(6):471-9
pubmed: 18623157
Nat Mater. 2004 Jan;3(1):58-64
pubmed: 14661016
Biomaterials. 2016 Oct;105:38-51
pubmed: 27505621
Int J Mol Sci. 2019 Nov 21;20(23):
pubmed: 31766475
Biomater Sci. 2019 Oct 1;7(10):4112-4130
pubmed: 31359013
Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7
pubmed: 23016643
ACS Appl Mater Interfaces. 2019 Dec 4;11(48):45276-45289
pubmed: 31638771
Stroke. 2013 Aug;44(8):2351-5
pubmed: 23715957
Biointerphases. 2012 Dec;7(1-4):2
pubmed: 22589045
ACS Biomater Sci Eng. 2015 Jun 8;1(6):431-439
pubmed: 26240838
PLoS One. 2016 Jan 22;11(1):e0147184
pubmed: 26799619
Clin Microbiol Rev. 2010 Oct;23(4):858-83
pubmed: 20930076
Cell. 2008 Feb 22;132(4):645-60
pubmed: 18295581
Theranostics. 2020 Jul 9;10(18):8227-8249
pubmed: 32724468
Biomed Pharmacother. 2019 May;113:108661
pubmed: 30836275
J Am Chem Soc. 2002 Sep 18;124(37):10954-5
pubmed: 12224923
Curr Opin Neurol. 2013 Dec;26(6):617-25
pubmed: 24136128
Clin Pharmacol Ther. 2015 Nov;98(5):492-501
pubmed: 26250447
Brain Res. 2019 Oct 15;1721:146325
pubmed: 31325424
Eur J Pharm Sci. 2020 May 30;148:105314
pubmed: 32200044
Int J Pharm. 2011 Oct 31;419(1-2):296-307
pubmed: 21821107
Nanomedicine. 2015 Apr;11(3):751-67
pubmed: 25645958
Stem Cells Int. 2015;2015:948040
pubmed: 26124844
Biochem Biophys Res Commun. 2016 Jan 22;469(4):830-5
pubmed: 26707645
Neurotherapeutics. 2019 Jan;16(1):166-175
pubmed: 30542906
Alzheimers Dement (N Y). 2021 Mar 31;7(1):e12155
pubmed: 33816762